A Phase 2, Multicentre, Open-Label, Umbrella Study of SCIB1 and iSCIB1+ in Patients With Advanced Unresectable Melanoma Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)
Latest Information Update: 09 Jun 2025
At a glance
- Drugs Pembrolizumab (Primary) ; SCIB 1 (Primary) ; Ipilimumab; Nivolumab
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms SCOPE study
- Sponsors Scancell
Most Recent Events
- 30 Apr 2025 Results presented at the 116th Annual Meeting of the American Association for Cancer Research
- 14 Apr 2025 According to the Scancell holdings Media Release, The SCOPE study will enrol over 140 patients across four cohorts,Data from all study cohorts in this trial will inform the design of the upcoming randomized trial, which is planned for in H2 2026, either by Scancell or in partnership. Clinical data from SCIB1in cohort 1 and iSCIB1+ in cohort 3 is expected around mid-2025, while clinical data from iSCIB1+in cohort 4, following the partnership with CVLP, is expected late 2025.
- 14 Apr 2025 According to the Scancell holdings Media Release, the company announces a partnership with the NHS Cancer Vaccine Launch Pad (CVLP) tofast-track access for NHS patients into the fourth cohort of this study. This cohort will evaluate intradermal administration of Scancell iSCIB1+, potent, targeted off-the-shelf Immunobody, second generation DNA cancer vaccine, in patients with advanced unresectable melanoma receiving standard of care immunotherapy treatments.